# Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma

> **NCT03390595** · PHASE2 · COMPLETED · sponsor: **Associació per a la Recerca Oncologica, Spain** · enrollment: 85 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **COMBINATION_PRODUCT:** avelumab 10mg/kg with carboplatin/gemcitabine
- **COMBINATION_PRODUCT:** carboplatin/gemcitabine alone

## Key facts

- **NCT ID:** NCT03390595
- **Lead sponsor:** Associació per a la Recerca Oncologica, Spain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-17
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03390595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03390595, "Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03390595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*